# Arcutis Biotherapeutics share price today (Arcutis Biotherapeutics, Inc., ARQT)

> Arcutis Biotherapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. ARQT · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/arqt

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $27.00 (+11.4% in a year)
- P/E: 124.5×, against its own history
- Revenue (Jun 2026): $130 M (+59.3% on a year ago)
- Profit (Jun 2026): $15.0 M
- Operating margin: 12.7% (+30.6 points on a year ago)
- ROE: −9%, FY25

Biggest thing to watch: the price has already been rising for 5 weeks, so timing is the risk more than the business. ## What is the Arcutis Biotherapeutics share price today? Arcutis Biotherapeutics, Inc.'s share price was $27.00 at the close on 5 November 2026. It has been rising for 5 weeks. That is 6.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between $21 and $32, and at that close it sat 55% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 3 weeks in a row. Over the last 6.7 years the share price moved +2% while the S&P 500 moved +121%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Arcutis Biotherapeutics pay? Arcutis Biotherapeutics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Arcutis Biotherapeutics on? Arcutis Biotherapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Arcutis Biotherapeutics profitable? Arcutis Biotherapeutics, Inc. earned $15.0 M of net profit in the Jun 2026 quarter. The full FY25 year was a loss of $16.1 M. That is 11.6% of the quarter's revenue. The same quarter a year earlier lost $15.9 M. 9 of the last 12 reported quarters were loss-making. ## How much revenue does Arcutis Biotherapeutics make, and is it growing? Arcutis Biotherapeutics, Inc. reported $130 M of revenue in the Jun 2026 quarter, +59.3% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 3 years it has grown 367.3% a year on average. The last full year, FY25, came in at $376 M. The last four reported quarters add to $464 M. FY25 revenue was $376 M, +91.3% on the year before. Recent pace: the last four quarters grew +80.7% on average, against 367.3% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +76.1%, against +87.4% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does Arcutis Biotherapeutics keep? Arcutis Biotherapeutics, Inc.'s operating margin was 12.7% in the Jun 2026 quarter, 30.6 percentage points higher than the same quarter a year ago. Across 4 years it has been between −8,183.0% and −3.3%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +30.6 percentage points on the year while gross margin changed +0.8 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Arcutis Biotherapeutics' profit turning into cash? Arcutis Biotherapeutics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $5.6 M of cash, against −$16.1 M of profit. After $686 K of spending on assets, free cash was −$6.3 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Arcutis Biotherapeutics' cash go? Arcutis Biotherapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $1.3 M on assets over the last 3 years. Averaged over those years that is 0.1% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $1.3 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Arcutis Biotherapeutics' P/E ratio, and how does it compare with its own history? Arcutis Biotherapeutics, Inc.'s P/E is 124.5×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Arcutis Biotherapeutics business getting better or worse? Arcutis Biotherapeutics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 9 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Arcutis Biotherapeutics earn on its capital? Arcutis Biotherapeutics, Inc. earned a ROE of −9% in FY25. That is up from a low of −296% in FY23. Its return on capital used (ROIC) is left out: on sales this small it reads −1,152%, a number that says nothing useful about the business. It comes from a −4.3% net margin and 0.87× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −4.3% net margin × 0.87× asset turnover × 2.29× leverage (assets divided by equity) ≈ −8.6% on equity. The margin does its share; borrowing is a big part of it. ## Does Arcutis Biotherapeutics have too much debt? Arcutis Biotherapeutics, Inc. has total debt of $114 M against shareholder equity of $221 M as of Jun 2026, so its debt is 0.52× its equity. Year by year, that ratio went from 0.26 in FY21 to 0.60 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Arcutis Biotherapeutics shareholding pattern? 21.8% of Arcutis Biotherapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 6.1 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Arcutis Biotherapeutics from balance-sheet trouble? For Arcutis Biotherapeutics, Inc., the Z-score is 5.61. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 5.61 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Arcutis Biotherapeutics rank in its industry? There is no score against its industry: Arcutis Biotherapeutics, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Arcutis Biotherapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Arcutis Biotherapeutics in size? Arcutis Biotherapeutics is the 55th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: AbCellera Biologics Inc., Tango Therapeutics, Inc. and Iovance Biotherapeutics, Inc. Just below it: Telix Pharmaceuticals, Tarsus Pharmaceuticals, Inc. and Viridian Therapeutics, Inc. ### Biotechnology companies close in size

1. [AbCellera Biologics Inc.](https://www.sectoralpha.in/us/stocks/abcl) $3.6 billion
2. [Tango Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/tngx) $3.5 billion
3. [Iovance Biotherapeutics, Inc.](https://www.sectoralpha.in/us/stocks/iova) $3.5 billion
4. Arcutis Biotherapeutics, Inc. $3.4 billion
5. [Telix Pharmaceuticals Limited](https://www.sectoralpha.in/us/stocks/tlx) $3.3 billion
6. [Tarsus Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/tars) $3.3 billion
7. [Viridian Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/vrdn) $3.2 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Dave Inc.](https://www.sectoralpha.in/us/stocks/dave) $4.3 billion · Software - Application
2. [Sportradar Group AG](https://www.sectoralpha.in/us/stocks/srad) $4.3 billion · Software - Application
3. Arcutis Biotherapeutics, Inc. $4.3 billion
4. [Warrior Met Coal, Inc.](https://www.sectoralpha.in/us/stocks/hcc) $4.3 billion · Coking Coal
5. [California Resources Corporation](https://www.sectoralpha.in/us/stocks/crc) $4.3 billion · Oil & Gas Exploration & Production

## What else do people ask about Arcutis Biotherapeutics? ### What were Arcutis Biotherapeutics's latest quarterly results? Arcutis Biotherapeutics, Inc. reported revenue of $130 M and net profit of $15.0 M for the Jun 2026 quarter. Earnings per share were $0.11. The operating margin was 12.7%, 30.6 percentage points higher than a year earlier (as of 5 November 2026). ### What is Arcutis Biotherapeutics's market cap? Arcutis Biotherapeutics, Inc.'s market capitalisation is $3.4 B at a stock price of $27.00. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Arcutis Biotherapeutics performing? Arcutis Biotherapeutics, Inc.'s share price has been rising for 5 weeks. Over the past 13 weeks it has done better than the S&P 500, for 3 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Arcutis Biotherapeutics's stock price go up? This page does not forecast Arcutis Biotherapeutics, Inc.'s stock price. What it shows instead: the stock price is $27.00, and it has been rising for 5 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Does Arcutis Biotherapeutics have too much debt? Arcutis Biotherapeutics, Inc. has a moderate amount of debt: its debt is 0.51× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. Keep that borrowing in mind when reading the returns on this page (as of 5 November 2026). ### Where is Arcutis Biotherapeutics in its business cycle? Arcutis Biotherapeutics, Inc.'s FY25 operating margin was −3.3%, against a 4-year range of −8,183.0% to −3.3%: the middle of its own range, neither a peak nor a low. The latest quarter was 12.7%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the Arcutis Biotherapeutics story? Biggest thing to watch: the price has already been rising for 5 weeks, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Arcutis Biotherapeutics a stock worth studying right now? What the numbers show: Arcutis Biotherapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.